Comparative Pharmacology
Head-to-head clinical analysis: BASAGLAR versus MYXREDLIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BASAGLAR versus MYXREDLIN.
BASAGLAR vs MYXREDLIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin glargine is a recombinant human insulin analog with a prolonged duration of action due to precipitation at the injection site, providing a constant basal insulin supply. It binds to the insulin receptor, activating downstream signaling pathways that promote glucose uptake, glycogen synthesis, and lipogenesis while inhibiting gluconeogenesis and glycogenolysis.
Insulin analog with rapid onset of action; lowers blood glucose by promoting peripheral glucose uptake and inhibiting hepatic glucose production, and by inhibiting lipolysis and proteolysis.
Subcutaneous injection, initial dose 0.2-0.4 units/kg/day, titrated to target glycemic control; typical maintenance 0.5-1.0 units/kg/day
0.5 mg or 0.75 mg subcutaneously once daily, initially, with titration based on glycemic response; maximum dose 1.5 mg/day.
None Documented
None Documented
13.2 hours (range 10.0-20.6 hours) for insulin glargine; reflects extended duration after subcutaneous injection.
Terminal elimination half-life 12-15 hours in adults; prolonged to 24-30 hours in renal impairment (CrCl <30 mL/min)
Renal: minimal (<1% as unchanged drug); hepatic metabolism to inactive metabolites; fecal: not significant.
Renal excretion 70% as unchanged drug; fecal/biliary elimination 30% as metabolites
Category C
Category C
Long-acting Insulin
Long-acting Insulin